Welcome to our dedicated page for ACLARION news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on ACLARION stock.
About Aclarion Inc.
Aclarion Inc. (Nasdaq: ACON, ACONW) is a pioneering healthcare technology company that combines advanced Magnetic Resonance Spectroscopy (MRS), proprietary biomarkers, and augmented intelligence algorithms to transform the diagnosis and treatment of chronic low back pain (cLBP). The company’s flagship product, Nociscan, is the first evidence-supported, noninvasive Software-as-a-Service (SaaS) platform designed to help physicians distinguish between painful and nonpainful discs in the lumbar spine. By providing critical insights into the physiological state of intervertebral discs, Nociscan enables more precise and personalized treatment strategies for patients suffering from degenerative spine conditions.
Innovative Technology and Core Offerings
Aclarion’s Nociscan platform leverages the power of MRS, a technology integrated into standard MRI machines, to analyze chemical biomarkers associated with disc pain. Through a secure cloud connection, MRS data is processed using proprietary algorithms that quantify biomarkers indicative of discogenic pain. The resulting reports provide actionable insights for medical professionals, enhancing diagnostic accuracy and optimizing clinical decision-making. Nociscan is particularly valuable in addressing the diagnostic challenges of cLBP, a condition affecting millions globally and representing a significant economic burden on healthcare systems.
Market Position and Revenue Model
Aclarion operates within the $134.5 billion U.S. low back and neck pain market, focusing on the intersection of healthcare and technology. Its revenue model is centered on the delivery of Nociscan reports to medical professionals via a subscription-based SaaS platform. Substantially all of the company’s revenue is generated from contracts with customers in the United States, with growing international adoption driven by strategic partnerships and clinical validation.
Strategic Growth and Industry Impact
Aclarion’s strategy to achieve widespread adoption of Nociscan includes partnerships with Key Opinion Leaders (KOLs), participation in clinical trials, and securing payer coverage. The company has demonstrated success in markets like the UK, where leading private insurers have begun reimbursing Nociscan. Additionally, Aclarion collaborates with research institutions and healthcare providers to generate robust clinical and economic evidence supporting the efficacy and cost-effectiveness of its technology. The company’s innovative approach positions it as a disruptor in the spine care industry, with the potential to redefine standard diagnostic and treatment paradigms.
Commitment to Innovation
Aclarion continues to expand its intellectual property portfolio, with 24 issued U.S. patents covering advancements in MRS and biomarker analysis. The company is also exploring the application of artificial intelligence (AI) and machine learning to enhance the accuracy and efficiency of its solutions. These innovations underscore Aclarion’s commitment to leveraging cutting-edge technology to address unmet needs in chronic pain management.
Conclusion
With its groundbreaking Nociscan platform and a clear focus on clinical and economic validation, Aclarion Inc. is well-positioned to drive significant improvements in the diagnosis and treatment of chronic low back pain. By combining advanced technology, strategic partnerships, and a robust evidence base, the company is paving the way for a new era in spine care and personalized medicine.
Aclarion (Nasdaq: ACON) has secured its first commercial agreement with Scripps Health in San Diego, expanding access to its Nociscan technology. The agreement brings the diagnostic solution to Southern California's largest healthcare system, serving over 3.2M people in the San Diego Metro area.
Nociscan, which uses MR Spectroscopy and AI to identify chronic low back pain sources, will be available at Scripps Green Hospital. Dr. Robert Eastlack, Orthopedic Surgeon at Scripps Health, emphasized the technology's value in providing additional diagnostic information for patients previously referred to Beverly Hills for the procedure.
Scripps Health operates five hospitals and 19 outpatient facilities, treating 500,000 patients annually through 2,600 affiliated physicians. The system will implement Nociscan both in clinical practice and research trials, supporting their mission to advance spine care.
Aclarion (NASDAQ: ACON), a healthcare technology company specializing in MRS and AI for back and neck pain treatment optimization, has announced the adjournment of its Special Meeting of Stockholders originally scheduled for February 28, 2025.
The meeting has been rescheduled to March 5, 2025, at 9:30 a.m. Mountain Time at the company's Broomfield, Colorado office. The adjournment aims to solicit additional votes for proposals outlined in the company's proxy statement filed with the SEC on February 3, 2025.
The record date remains January 6, 2025. Previously submitted proxies will remain valid unless revoked. Shareholders can modify their votes until 11:59 p.m. Mountain Time on March 4, 2025, either through Internet voting or by submitting a new signed proxy.
Aclarion (Nasdaq: ACON) announced its participation in the 2025 Spine Summit, where Dr. Nicholas Theodore will showcase the company's NOCISCAN technology. NOCISCAN is a pioneering SaaS platform that combines MR Spectroscopy with augmented intelligence to help physicians identify the location of chronic low back pain.
Dr. Theodore, who serves as Professor at Johns Hopkins University School of Medicine and holds multiple director positions, will present 'NOCISCAN, Augmented Intelligence, and Low Back Pain Decision Support' on February 21, 2025. The technology is particularly significant given that approximately 266 million people worldwide suffer from degenerative spine disease and low back pain.
NOCISCAN is the first evidence-supported platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine by objectively quantifying chemical biomarkers associated with disc pain.
Aclarion (NASDAQ: ACON) has received its 24th US patent through a Notice of Allowance from the USPTO. This patent expands the company's ability to use Magnetic Resonance Spectroscopy (MRS) for identifying propionic acid (PA) throughout the body as a potential biomarker for infection and pain. Previously, Aclarion's patents PA identification by MRS to intervertebral discs only.
The company's technology leverages MRS, a capability of common MRI scanners, to analyze chemical biomarkers within soft tissues. While traditional MRS post-processing faces challenges in generating quality data, Aclarion's patented innovations address these limitations, ensuring more reliable spectral data analysis for their Nociscan solution and other MRS applications.
Aclarion (NASDAQ: ACON) has announced Northwestern Medicine as the first site for its pivotal CLARITY trial, designed to demonstrate Nociscan's clinical and economic value in spine surgery. Northwestern Medicine, which led over 6,900 clinical studies with 372,561 participants in 2024, will participate in this groundbreaking randomized controlled trial.
The CLARITY trial is a fully funded, prospective, multi-center study that will evaluate 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain. The study will compare surgical outcomes between surgeons who are blinded and unblinded to Nociscan results. Nociscan is the first evidence-supported SaaS platform that helps physicians distinguish between painful and nonpainful discs in the lumbar spine through MR Spectroscopy and AI technology.
Aclarion (NASDAQ: ACON) announced that its Nociscan product is featured in the RSNA Edition of Siemens Healthineers magazine, MAGNETOM Flash. The article showcases how physicians incorporate Nociscan into their clinical practices for chronic low back pain patients. Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively distinguish between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain. The feature will be highlighted at the RSNA annual meeting from December 1-4, 2024, and is expected to serve as a valuable reference for the medical community.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the upcoming Virtual Investor Summit Microcap Event on November 21st, 2024. The company will deliver a presentation from 3:30 PM to 4:00 PM ET and will be available for one-on-one meetings throughout the day.
The event will showcase 40 micro-cap companies with catalysts and strong market performance. The presentation will be accessible via webcast, and qualified investors can register for complimentary access to participate in live Q&A sessions.
Aclarion (Nasdaq: ACON, ACONW), a healthcare technology company specializing in chronic low back pain location identification through biomarkers and AI algorithms, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , is scheduled for October 15, 2024.
CEO Brent Ness will represent Aclarion in a fireside chat at 2:00 PM ET. The summit will feature presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology.
Maxim senior analysts will host these sessions, providing insights into the participating companies. Interested parties can reserve their seats for the virtual event through a provided link.
Aclarion, Inc. (Nasdaq: ACON) announced that its Nociscan AI solution played a key role in a study to better understand Modic changes (MC) in chronic low back pain (cLBP) patients. The study, presented at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024, utilized Nociscan to measure intradiscal propionic acid (PA) levels adjacent to vertebral endplates with MC.
The research, conducted by the REACH Center at UCSF, aimed to clarify the biopsychosocial mechanisms of cLBP. Results suggest that PA levels may be useful in understanding why some MC patients improve or respond to treatment while others do not. Nociscan's ability to noninvasively quantify chemical biomarkers associated with disc pain could potentially lead to personalized treatment plans for cLBP patients, including the possibility of using antibiotics as a first-line treatment for those with high PA levels.
Aclarion, Inc. (Nasdaq: ACON) has provided a corporate update on their Nociscan AI technology, which aids in identifying chronic low back pain sources. Key milestones include:
1. Three of four largest private UK insurers now cover Nociscan
2. Partnership with ten prominent KOL surgeons in the US
3. Strategic partnership with ATEC to expand KOL network
4. Multiple commercial agreements in key US markets
5. Participation in NIH's BEST Trial with 800+ patients
6. Launch of CLARITY, a flagship clinical study
The company's technology is protected by 23 US patents and 17 international patents. Aclarion aims to establish Nociscan as a standard of care for chronic low back pain, addressing a $134 billion annual healthcare expenditure in the US.
FAQ
What is the current stock price of ACLARION (ACONW)?
What is Aclarion Inc.'s core business?
What is Nociscan?
How does Aclarion generate revenue?
What makes Aclarion's technology unique?
What is the market potential for Aclarion's solutions?
What challenges does Aclarion face in its market?
What role does AI play in Aclarion's solutions?
What is Aclarion's intellectual property portfolio?
How is Aclarion expanding its market presence?
What is Aclarion's long-term vision?
